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Abstract ToevaluatetheresponsivenessofpowerDoppler
ultrasonography (PDUS) in comparison with conventional
measures of disease activity and structural damage in rheu-
matoid arthritis (RA) patients receiving tocilizumab (TCZ).
Seven RA patients with active arthritis were enrolled in the
study andprospectively monitored for 12 months. Theywere
treatedwithTCZ(8 mg/kg)every4 weeksasmonotherapyor
in combination with disease-modifying antirheumatic drugs
(DMARDs). Clinical, laboratory, and ultrasound examina-
tions were conducted at baseline, 1, 3, 6, 9, and 12 months.
Power Doppler (PD) signals were graded from 0 to 3 in 24
joints, and total PD score was calculated as the sum of scores
ofindividualjoints.One-yearradiographicprogression ofthe
handswasestimatedbyusingGenant-modiﬁedSharpscoring.
Theaveragesoftheclinicalparametersrapidlyimproved,and
allpatientsachievedgoodresponsewithin6 monthsbasedon
standard 28-joint Disease Activity Score (DAS28). Although
the average total PD score declined in parallel with clinical
improvement, radiography of the hands showed progression
of destruction in the joints where PD signals remained, even
among clinical responders. DSharp score correlated with the
time-integrated value (TIV) of total PD scores (Dtotal Sharp
score: r = 0.77, P = 0.04; Derosion: r = 0.78, P = 0.04;
Djoint-space narrowing (JSN): r = 0.75, P = 0.05), but not
withTIVsofclinicalparametersincludingDAS28.PDUScan
independently evaluate disease activity in RA patients
receiving TCZ and is superior to DAS28, especially in pre-
dicting joint destruction.
Keywords Joint destruction  PDUS 
Rheumatoid arthritis  Tocilizumab
Introduction
Tocilizumab (TCZ), a humanized anti-IL-6 receptor anti-
body, has been shown in previous clinical trials to not only
improve the symptoms of rheumatoid arthritis (RA) but
also prevent progressive joint destruction among patients
with moderate to severe RA refractory to conventional
disease-modifying antirheumatic drugs (DMARDs) when
administered either as monotherapy or in combination with
conventional DMARDs [1–6]. Also, the results of the
RADIATE study suggest that TCZ is a safe and effective
alternative for patients who fail to respond to antitumor
necrosis factor (TNF) therapy [7]. TCZ was approved for
clinical use against RA in Japan in April 2008. Since then it
has been conﬁrmed in actual clinical practice that TCZ is
effective for treating RA patients refractory to conventional
DMARDs or anti-TNF agents [8–10].
However, evaluating clinical activity in RA patients
receiving TCZ is difﬁcult because TCZ blocks IL-6 sig-
naling and rapidly suppresses the serum levels of C-reac-
tive protein (CRP) and erythrocyte sedimentation rate
(ESR) which are components of the Disease Activity Score
in 28 joints (DAS28).
Over the past decade, musculoskeletal ultrasonography
(MSUS) has been established as a new imaging modality for
assessingRA-affected joints. Ultrasonographyisreportedto
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the detection of synovial hypertrophy, effusion, and
inﬂammatory activity [11–14]. Power Doppler ultrasonog-
raphy (PDUS) in particular detects synovial perfusion in the
inﬂamed joints, and a decrease in composite power Doppler
(PD) signal scores in response to treatment, correlates sig-
niﬁcantly with DAS28 score, and with CRP and ESR [11,
15]. PDUS is also a useful tool in monitoring patients under
TNF antagonist therapy, and PDUS ﬁndings have a predic-
tive value in radiographic outcomes [16–19].
In this study, we prospectively monitored joint lesions
by ultrasonography for the ﬁrst 12 months of TCZ therapy
and evaluated the responsiveness of ultrasonography
compared with conventional measures of disease activity
and structural damage.
Patients and methods
Patients
Seven patients with RA according to the American College
of Rheumatology (formerly, the American Rheumatism
Association) 1987 criteria [20], who were refractory to
DMARDs, including TNF inhibitors, were enrolled in the
study. They were treated with TCZ (8 mg/kg) every
4 weeks with/without DMARDs and low-dose predniso-
lone. The patients underwent clinical, laboratory, and
PDUS evaluation at baseline, 1, 3, 6, 9, and 12 months.
Radiographs of the hands were obtained at baseline and
after 12 months. The study was conducted in accordance
with the Declaration of Helsinki, and informed consent was
obtained from all patients before study enrollment.
Clinical and laboratory assessment
At each visit, patients were evaluated clinically by the
same physicians who assessed 28 joints (the bilateral gle-
nohumeral, elbow, and wrist joints, metacarpophalangeal
joints, proximal interphalangeal joints of the ﬁngers, and
knee joints) for tenderness and swelling. The general VAS
(gVAS, 100-mm visual analog scale) was rated individu-
ally for each patient.
CRP as an inﬂammatory marker and MMP-3 (matrix
metalloproteinase-3) were measured. Disease activity was
estimated by calculating DAS28 based on CRP and Clin-
ical Disease Activity Index (CDAI).
PDUS assessment
PDUS was performed by two well-trained rheumatologists:
One scanned target joints to obtain images, and both agreed
on the assessment of the PD score. They were blind to the
clinical, laboratory, and radiographic ﬁndings. An Aplio
SSA-700A (Toshiba, Tokyo, Japan) with linear array
transducers (12 MHz for ﬁngers and hands, 7.5 MHz for
knees) was used in this study. The ultrasound scanning
method has been described previously [21–24]. Of the 28
joints, 24 (excluding bilateral glenohumeral and elbow
joints) were assessed by PDUS. The joints were scanned
longitudinally and transversally from the dorsal view. PD
imaging was performed by selecting a region of interest
that included the bony margins and synovial site. PD sig-
nals in each joint were graded on a semiquantitative scale
of 0–3 (0: absent [no synovial ﬂow]; 1: mild [single-vessel
signal or isolated signals]; 2: moderate [conﬂuent signals in
less than half of the synovial area]; 3: marked [signals in
more than half of the synovial area]), corresponding to the
maximum score obtained from the synovial sites evaluated
in each joint [11]. Total PD score was calculated as the sum
of individual scores for each joint at each examination.
For calculating intraobserver reliability, ultrasound
investigators scored the PD signals of 50 images randomly
selected from stored images and then evaluated again the
same selected images arranged in a different order after an
interval. Interobserver reliability was evaluated by using
the ﬁrst-assessed scores.
Radiographic assessment
Two radiologists who were unaware of the clinical and
ultrasound ﬁndings measured structural damage of the
hands at baseline and at 12 months by using the Genant-
modiﬁed Sharp scoring system; total score (with a maxi-
mum possible score of 200) was composed of erosion score
(maximum possible 100) plus joint-space narrowing score
(JSN, maximum possible 100) [25, 26].
Interobserver reliability was assessed by comparing
baseline scores.
Statistical analysis
The data are reported as mean ± SE. The paired t-test was
used to test for differences. Correlations between each of
the clinical, laboratory, and ultrasound parameters were
obtained by Pearson’s correlation coefﬁcient. To compare
these parameters with radiographic progression, changes in
each parameter during the study were evaluated by calcu-
lating time-integrated values (TIV) throughout the year
using the area under the curve (AUC) method [27]. P val-
ues less than 0.05 were considered to be statistically
signiﬁcant.
Intraobserver reliability for the PD score of each joint
was estimated by calculating the intraclass correlation
coefﬁcient (ICC). Interobserver reliabilities for PD score
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Cohen’s kappa value. Kappa value \0.40 was poor,
0.40–0.50 moderate, 0.50–0.70 good, and 0.70–1 excellent.
Results
Patient characteristics
All patients completed the study without any severe
adverse effects. Baseline characteristics of patients are
shown in Table 1. All were women and refractory to one or
more conventional DMARDs. Five patients had received
anti-TNF agents previously, but switched to TCZ because
of inefﬁcacy or adverse effects. Methotrexate, azathioprine,
and prednisolone were used in combination with TCZ in 5,
1, and 5 patients, respectively.
Course of clinical, laboratory, and PDUS ﬁndings
At baseline, total PD score of each patient correlated with
tender joint count (TJC) (r = 0.90, P = 0.02), but not with
other clinical parameters including CRP and DAS28.
The means of clinical parameters TJC, gVAS,CDAI, and
DAS28 rapidly improved within 3 months, and at the
6-month visit all patients had achieved a good response
based on DAS28 and the criteria of the European League
against Rheumatism (Table 2). Rapid normalization of
serum CRP levels of each patient was observed. Serum
MMP-3 levels of each patient also decreased, correlating
wellwithserumCRPlevelsatbaseline(r = 0.86,P = 0.03)
and at 1 month (r = 0.99, P = 0.0003). The changes in
values of each patient’s clinical and laboratory parameters
tendedtofollowtheaverage.Ontheotherhand,althoughthe
average total PD score appeared to decline in parallel with
clinical improvement, the changes in each patient’s total PD
score were diverse (Fig. 1): 1 patient (Pt. 5) with high total
PD score at baseline experienced a dramatic decrease in PD
signalsonlyafter2coursesofTCZinfusions;anotherpatient
(Pt. 2) did not obtain a response until 12 months; and in 1
patient(Pt.3)thescoreincreasedwithaclinicalexacerbation
at 9 months.
Radiographic progression
Radiographic progression of joint destruction was detected
in 5 patients; mean Dtotal Sharp score of these patients was
3.78 (range 1.02–10.9), mean Derosion score was 2.24
(range 1.02–6.12), and mean DJSN score was 1.54 (range
0–4.81). Among them, 1 was a ﬂare-up but the rest were
evaluated by clinical assessments as responding to TCZ
treatment.
Predictors of ﬁnal activity and joint destruction
To analyze which of the parameters could predict ﬁnal
disease activity and joint destruction, correlations between
the TIV of each parameter and DAS28 at 12 months and
DSharp score were calculated. TIVs of clinical parameters
including gVAS, CDAI, and DAS28 correlated signiﬁ-
cantly with ﬁnal DAS28 (gVAS: r = 0.90, P = 0.01;
CDAI: r = 0.82, P = 0.04; DAS28: r = 0.85, P = 0.03),
but no relationship with joint destruction was observed. On
the other hand, TIV of total PD scores correlated with
DSharp score (Dtotal; r = 0.77, P = 0.04, Derosion;
r = 0.78, P = 0.04, DJSN; r = 0.75, P = 0.05), but not
with ﬁnal DAS28.
Comparison between 1-year radiographic progression
and cumulative PD scores in individual joints
Inﬂammation remaining in a joint is thought to be the main
cause of bone and cartilage destruction, and previous
studies have reported that the existence of synovial perfu-
sion detected by PDUS is related to subsequent radio-
graphic progression [17, 28, 29]. Based on these views, we
compared the TIVs of the PD scores for individual joints
(TIV-individual PD scores) throughout the study with the
Table 1 Baseline characteristics of the patients
Age/sex Duration of RA Stage Number of
previous DMARDs
Previous biologics Combination drugs
DMARDs Steroid
Pt. 1 71 F 10 years 3 2 IFX, ETN MTX 8 mg PSL 5 mg
Pt. 2 68 F 28 years 2 6 None AZP 100 mg PSL 6 mg
Pt. 3 74 F 16 years 3 6 ETN None PSL 5 mg
Pt. 4 54 F 1 year 6 months 2 1 IFX, ETN MTX 15.5 mg PSL 12.5 mg
Pt. 5 51 F 27 years 4 2 IFX MTX 10.5 mg PSL 5 mg
Pt. 6 49 F 2 years 2 1 IFX MTX 6 mg None
Pt. 7 73 F 1 year 3 months 2 2 None MTX 8 mg None
Pt. patient, IFX inﬂiximab, ETN etanercept, MTX methotrexate, AZP azathioprine, PSL prednisolone
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1231-year radiographic progression of the joint. The cut-off
point for TIV-individual PD scores predicting an increase
in total Sharp score was 16 as estimated by using receiver
operating characteristic (ROC) curve analysis and the
Youden index (AUC was 0.953, false positive fraction
0.034, true positive fraction 0.875). All but 1 of the joints
showing radiographic progression were joints whose TIV-
individual PD scores was 16 or more, and no progression of
joint destruction was seen among the joints with no PD
signals throughout the year (Fig. 2). Also, TIV-individual
PD scores of each joint correlated with DSharp score (total
score: r = 0.63, P\0.0001; erosion score: r = 0.64,
P\0.0001; JSN score: r = 0.58, P\0.0001) (Table 3).
Representative images are shown in Fig. 3.
Table 2 Mean ± SE values for clinical, laboratory, and PDUS parameters at the baseline and follow-up assessments
Parameter Baseline 1 month 3 months 6 months 9 months 12 months
TJC (0–28) 7.5 ± 1.2 4.8 ± 0.7 3.2 ± 0.9
 2 ± 0.6
 2.8 ± 0.8
 3.3 ± 1.6
SJC (0–28) 6.3 ± 1.4 7 ± 2.9 5.9 ± 2.1 5.1 ± 2.1 3.1 ± 1.0 2.7 ± 1.1
gVAS (0–100) 71.2 ± 7.0 45.7 ± 10.8
 19.7 ± 4.0
 19.3 ± 3.8
 26.3 ± 12.8
 22.3 ± 8.2
§
CDAI 26.9 ± 2.6 18.5 ± 2.6 12 ± 2.1
 8.9 ± 0.6
 10.6 ± 3.6
 9.8 ± 3.5

CRP, mg/dL 2.66 ± 1.30 0.21 ± 0.17 0.17 ± 0.15 0.12 ± 0.08 0.02 ± 0.01 0.03 ± 0.01
MMP-3, ng/mL 358.2 ± 100.5 234.9 ± 78.1 128.3 ± 22.1 107.1 ± 29.5 65.5 ± 9.38
 59.1 ± 13.2

DAS28 5.18 ± 0.23 3.58 ± 0.31
 2.84 ± 0.33
§ 2.59 ± 0.20
§ 2.59 ± 0.43
 2.47 ± 0.43

Total PD score 15 ± 5.3 11.7 ± 3.1 6.7 ± 2.6 5.6 ± 2.5 5.3 ± 2.4 4.3 ± 2.1

PDUS power Doppler ultrasonography, TJC tender joint count, SJC swollen joint count, gVAS visual analog scale for patient’s general
assessment, CDAI Clinical Disease Activity Index, CRP C-reactive protein, MMP-3 matrix metalloproteinase-3, DAS28 Disease Activity Score
in 28 joints calculated by using CRP
 P\0.05 versus the baseline data, by pairwise comparison
 P\0.01 versus the baseline data, by pairwise comparison
§ P\0.001 versus the baseline data, by pairwise comparison
Fig. 1 Changes in average and individual patients’ total PD scores.
The average total PD score appeared to decline gradually in parallel
with clinical improvement, but the changes in individual’s total PD
score were diverse
Fig. 2 Proportion of joints with damage, grouped by TIV of PD
scores of individual joints. Among the 12 joints with a TIV-individual
PD score of C16, erosion had progressed in 7 joints (58.3%), JSN in 6
joints (50%), and total Sharp score in 7 joints (58.3%). Among the 46
joints with a positive TIV-individual PD score of \16, only 1 joint
developed new erosion. No progression was seen among any of the
joints with a TIV-individual PD score of 0
Table 3 Correlation (r) between time-integrated value (TIV) of PD
scores of individual joints and radiographic progression
One-year radiographic progression
D Erosion score D JSN score D Total score
PIP/MCP 0.46
§ 0.40
§ 0.44
§
Wrist 0.79
 0.70
 0.75

All 0.64
§ 0.58
§ 0.63
§
PIP proximal interphalangeal joints, MCP metacarpophalangeal
joints, JSN joint-space narrowing
 P\0.01,
§ P\0.0001
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The intraobserver ICC for PD signals of each joint was
0.99 (95% conﬁdence interval [95% CI] 0.98–0.99), and
the interobserver kappa value was 0.92.
The interobserver kappa values for Sharp score were
0.96 for total score, 0.95 for erosion score, and 0.97 for
JSN score.
Discussion
Although all patients enrolled in this study were refrac-
tory to previous treatments including anti-TNF blockers,
they obtained more than moderate response after TCZ
therapy. Only 1 patient experienced an exacerbation.
Nonetheless, in some patients, progressive radiographic
damage was observed independent of clinical response.
In contrast to clinical assessments, the cumulative PD
signal indicated by the TIV of total PD scores was a
strong predictor for joint destruction in these individuals.
Moreover, when we focused on each joint, the relation-
ship between cumulative PD signal and joint destruction
was clearer: no joints without a PD signal had radio-
graphic progression of joint damage, whereas a high
TIV-individual PD score correlated with radiographic
progression both in erosion score and in JSN score.
These results suggest that a high cumulative PD signal,
which means PDUS detected long-lasting synovitis in
spite of TCZ treatment, can directly lead to joint
destruction with a high rate.
Naredo et al. reported the relationship between radio-
graphic progression and PDUS ﬁndings in 2 studies [17,
28]. Those studies showed that TIVs of PDUS parameters
correlated strongly with radiographic progression among
early RA treated with DMARDs and patients initiated with
anti-TNF blockers. Our observation is consistent with these
reports.
Fig. 3 Representative data. a Pt. 1. Residual Grade 2 PD signals were
detected in the wrist for at least 9 months (TIV-individual PD score
was 33). Carpal joint-space narrowing and erosion of the ulnar head
progressed throughout the study. b Pt. 5. After 2 courses of TCZ
infusions PD signals decreased dramatically in each joint (TIV-
individual PD scores of right 3PIP = 4.5, left 3PIP = 1.5, and left
3MCP = 8.5). No radiographic progression was seen in these joints.
PIP proximal interphalangeal joint, MCP metacarpophalangeal joint
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inﬂammatory markers such as CRP or ESR without
exception, regardless of ongoing synovitis. Although our
study presents preliminary data from only small numbers,
this is the ﬁrst time it has been shown that PDUS can
evaluate remaining synovitis which relates to joint damage
more sensitively than any other assessments included in
this study under TCZ therapy.
Increasedjointdamagemaycausefunctionalimpairment.
In this era of biological agents, the goal of RA treatment is
now to achieve not only clinical remission but also radio-
graphic remission and no disability. Anti-TNF agents have
excellent efﬁcacy in inhibiting radiographic progression
regardless of baseline levels of inﬂammatory markers,
treatment response, or disease activity after treatment [30–
34]. The SAMURAI study reported that the group receiving
TCZmonotherapyshowedlessradiographicchangethanthe
DMARDs group [2, 6]. However, joint damage still
increased signiﬁcantly over time in some patients under
these biologic therapies, and in such cases, we might
strengthen the treatment. This suggests that to achieve true
radiographic remission, the response to treatment should be
evaluated on a joint-by-joint basis in addition to using a
conventional clinical score such as DAS28. From this per-
spective, because a high cumulative PD score tends to relate
to joint destruction, PDUS is a powerful tool to monitor the
changeinsynovitisineachjointandishelpfulindecidingthe
appropriate treatment plan.
There were several limitations in this study. First of all,
the patients’ backgrounds were not uniform. Disease
duration, previous treatments, adverse prognostic factors,
and concomitant drugs were diverse among the patients.
Furthermore, there was no control group. However, the aim
of this study was to clarify the usefulness of PDUS in
comparison with conventional clinical parameters in eval-
uating treatment response and in predicting structural
damage especially. From this view, all of the enrolled
patients were worthy of evaluation because they presented
with moderate or greater disease activity at baseline and all
had the potential for joint destruction to progress.
Second, although many reports showed that at baseline
the composite PD score of several joints or modiﬁed
DAS28 calculated by using the number of PD positive
joints correlated well with DAS28 and CRP, in this study
there were no correlations between these parameters. One
explanation for this is that the baseline levels of CRP were
low in some patients despite high total PD scores.
Third, the PDUS assessment differed from the Sharp
scoring system in the method for assessing wrist lesions.
We evaluated each wrist by PDUS in 3 areas (carpal joint,
radiocarpal joint, and ulnocarpal joint), and the maximum
PD score of the 3 was decided as the wrist’s PD score. On
the other hand, in the Genant-modiﬁed Sharp scoring
system each wrist was divided into 4 areas to determine the
erosion score and 3 areas to determine JSN, and we
regarded damage in the wrist joint as ‘progressed’ when
progression was observed in at least 1 area. Therefore, we
could not analyze accurately whether the location of
residual PD signal corresponded with the site of radio-
graphic progression, and it is possible that the correlation
between DSharp score and TIV-individual PD score of the
wrist was overestimated.
Intra and interobserver reliabilities of PD scoring were
excellent. Those reliabilities were calculated by using
stored images, and we did not evaluate the reliability of
acquiring appropriate PDUS images. But in this study, 2
ultrasound operators were occupied with each scan, and
they double checked and conferred with each other to
decide the score, thus raising the precision in the PDUS
assessment.
In summary, this is the ﬁrst report of PDUS monitoring
of RA joint lesions in patients undertaking TCZ therapy.
Although large-scale examinations will be needed to obtain
clearer conclusions, we found that ultrasonography can
independently evaluate disease activity in RA patients
receiving TCZ and is superior to DAS28 especially in
predicting joint destruction.
Conﬂict of interest The authors declare that they have no com-
peting interests.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Genovese MC, McKay JD, Nasonov EL et al (2008) Interleukin-6
receptor inhibition with tocilizumab reduces disease activity in
rheumatoid arthritis with inadequate response to disease-modi-
fying antirheumatic drugs: the tocilizumab in combination with
traditional disease-modifying antirheumatic drug therapy study.
Arthritis Rheum 58:2968–2980
2. Nishimoto N, Hashimoto J, Miyasaka N et al (2007) Study of
active controlled monotherapy used for rheumatoid arthritis, an
IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic
beneﬁt from an x ray reader-blinded randomised controlled trial
of tocilizumab. Ann Rheum Dis 66:1162–1167
3. Nishimoto N, Ito K, Takagi N (2010) Safety and efﬁcacy proﬁles
of tocilizumab monotherapy in Japanese patients with rheumatoid
arthritis: meta-analysis of six initial trials and ﬁve long-term
extensions. Mod Rheumatol 20:222–232
4. Nishimoto N, Miyasaka N, Yamamoto K et al (2009) Study of
active controlled tocilizumab monotherapy for rheumatoid
arthritis patients with an inadequate response to methotrexate
(SATORI): signiﬁcant reduction in disease activity and serum
vascular endothelial growth factor by IL-6 receptor inhibition
therapy. Mod Rheumatol 19:12–19
1332 Rheumatol Int (2012) 32:1327–1333
1235. Smolen JS, Beaulieu A, Rubbert-Roth A et al (2008) Effect of
interleukin-6 receptor inhibition with tocilizumab in patients with
rheumatoid arthritis (OPTION study): a double-blind, placebo-
controlled, randomised trial. Lancet 371:987–997
6. Hashimoto J, Garnero P, van der Heijde D et al. (2010)
Humanized anti-interleukin-6-receptor antibody (tocilizumab)
monotherapy is more effective in slowing radiographic progres-
sion in patients with rheumatoid arthritis at high baseline risk for
structural damage evaluated with levels of biomarkers, radiog-
raphy, and BMI: data from the SAMURAI study. Mod Rheu-
matol. doi:10.1007/s10165-010-0325-3
7. Emery P, Keystone E, Tony HP et al (2008) IL-6 receptor inhi-
bition with tocilizumab improves treatment outcomes in patients
with rheumatoid arthritis refractory to anti-tumour necrosis factor
biologicals: results from a 24-week multicentre randomised pla-
cebo-controlled trial. Ann Rheum Dis 67:1516–1523
8. Hirabayashi Y, Ishii T, Harigae H (2010) Clinical efﬁcacy of
tocilizumab in patients with active rheumatoid arthritis in real
clinical practice. Rheumatol Int 30:1041–1048
9. Kawashiri SY, Kawakami A, Iwamoto N et al (2010) Switching
to the anti-interleukin-6 receptor antibody tocilizumab in rheu-
matoid arthritis patients refractory to antitumor necrosis factor
biologics. Mod Rheumatol 20:40–45
10. Nakashima Y, Kondo M, Harada H et al (2010) Clinical evalu-
ation of tocilizumab for patients with active rheumatoid arthritis
refractory to anti-TNF biologics: tocilizumab in combination
with methotrexate. Mod Rheumatol 20:343–352
11. Naredo E, Bonilla G, Gamero F, Uson J, Carmona L, Laffon A
(2005) Assessment of inﬂammatory activity in rheumatoid
arthritis: a comparative study of clinical evaluation with grey
scale and power Doppler ultrasonography. Ann Rheum Dis
64:375–381
12. Rees JD, Pilcher J, Heron C, Kiely PD (2007) A comparison of
clinical vs ultrasound determined synovitis in rheumatoid arthritis
utilizing gray-scale, power Doppler and the intravenous micro-
bubble contrast agent ‘Sono-Vue’. Rheumatology (Oxford)
46:454–459
13. Cheung PP, Dougados M, Gossec L (2010) Reliability of ultra-
sonography to detect synovitis in rheumatoid arthritis: a sys-
tematic literature review of 35 studies (1, 415 patients). Arthritis
Care Res (Hoboken) 62:323–334
14. Kane D, Balint PV, Sturrock RD (2003) Ultrasonography is
superior to clinical examination in the detection and localization
of knee joint effusion in rheumatoid arthritis. J Rheumatol
30:966–971
15. Hameed B, Pilcher J, Heron C, Kiely PD (2008) The relation
between composite ultrasound measures and the DAS28 score, its
components and acute phase markers in adult RA. Rheumatology
(Oxford) 47:476–480
16. Iagnocco A, Perella C, Naredo E et al (2008) Etanercept in the
treatment of rheumatoid arthritis: clinical follow-up over one year
by ultrasonography. Clin Rheumatol 27:491–496
17. Naredo E, Moller I, Cruz A, Carmona L, Garrido J (2008) Power
Doppler ultrasonographic monitoring of response to anti-tumor
necrosis factor therapy in patients with rheumatoid arthritis.
Arthritis Rheum 58:2248–2256
18. Iagnocco A, Filippucci E, Perella C et al (2008) Clinical and
ultrasonographic monitoring of response to adalimumab treat-
ment in rheumatoid arthritis. J Rheumatol 35:35–40
19. Terslev L, Torp-Pedersen S, Qvistgaard E et al (2003) Effects of
treatment with etanercept (Enbrel, TNRF:Fc) on rheumatoid
arthritis evaluated by Doppler ultrasonography. Ann Rheum Dis
62:178–181
20. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American
Rheumatism Association 1987 revised criteria for the classiﬁca-
tion of rheumatoid arthritis. Arthritis Rheum 31:315–324
21. Wakeﬁeld RJ, Balint PV, Szkudlarek M et al (2005) Musculo-
skeletal ultrasound including deﬁnitions for ultrasonographic
pathology. J Rheumatol 32:2485–2487
22. Filippucci E, Iagnocco A, Meenagh G et al (2007) Ultrasound
imaging for the rheumatologist VII. Ultrasound imaging in
rheumatoid arthritis. Clin Exp Rheumatol 25:5–10
23. Filippucci E, Iagnocco A, Meenagh G et al (2006) Ultrasound
imaging for the rheumatologist II. Ultrasonography of the hand
and wrist. Clin Exp Rheumatol 24:118–122
24. Backhaus M, Burmester GR, Gerber T et al (2001) Guidelines for
musculoskeletal ultrasound in rheumatology. Ann Rheum Dis
60:641–649
25. Genant HK (2001) Interleukin-1 receptor antagonist treatment of
rheumatoid arthritis patients: radiologic progression and corre-
lation of Genant/Sharp and Larsen scoring methods. Semin
Arthritis Rheum 30:26–32
26. Genant HK, Jiang Y, Peterfy C, Lu Y, Redei J, Countryman PJ
(1998) Assessment of rheumatoid arthritis using a modiﬁed
scoring method on digitized and original radiographs. Arthritis
Rheum 41:1583–1590
27. Matthews JN, Altman DG, Campbell MJ, Royston P (1990)
Analysis of serial measurements in medical research. BMJ
300:230–235
28. Naredo E, Collado P, Cruz A et al (2007) Longitudinal power
Doppler ultrasonographic assessment of joint inﬂammatory
activity in early rheumatoid arthritis: predictive value in disease
activity and radiologic progression. Arthritis Rheum 57:116–124
29. Brown AK, Conaghan PG, Karim Z et al (2008) An explanation
for the apparent dissociation between clinical remission and
continued structural deterioration in rheumatoid arthritis.
Arthritis Rheum 58:2958–2967
30. Smolen JS, Han C, Bala M et al (2005) Evidence of radiographic
beneﬁt of treatment with inﬂiximab plus methotrexate in rheu-
matoid arthritis patients who had no clinical improvement: a
detailed subanalysis of data from the anti-tumor necrosis factor
trial in rheumatoid arthritis with concomitant therapy study.
Arthritis Rheum 52:1020–1030
31. Smolen JS, Van Der Heijde DM, St Clair EW et al (2006) Pre-
dictors of joint damage in patients with early rheumatoid arthritis
treated with high-dose methotrexate with or without concomitant
inﬂiximab: results from the ASPIRE trial. Arthritis Rheum
54:702–710
32. Smolen JS, Han C, van der Heijde DM et al (2009) Radiographic
changes in rheumatoid arthritis patients attaining different disease
activity states with methotrexate monotherapy and inﬂiximab
plus methotrexate: the impacts of remission and tumour necrosis
factor blockade. Ann Rheum Dis 68:823–827
33. Landewe R, van der Heijde D, Klareskog L, van Vollenhoven R,
Fatenejad S (2006) Disconnect between inﬂammation and joint
destruction after treatment with etanercept plus methotrexate:
results from the trial of etanercept and methotrexate with radio-
graphic and patient outcomes. Arthritis Rheum 54:3119–3125
34. van der Heijde D, Klareskog L, Landewe R et al (2007) Disease
remission and sustained halting of radiographic progression with
combination etanercept and methotrexate in patients with rheu-
matoid arthritis. Arthritis Rheum 56:3928–3939
Rheumatol Int (2012) 32:1327–1333 1333
123